Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.
Fontein DBY, Houtsma D, Hille ETM, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, Guchelaar HJ, Gelderblom H, Dirix LY, Paridaens R, Bartlett JMS, Nortier JWR, van de Velde CJH; Dutch TEAM Steering Committee. Fontein DBY, et al. Among authors: seynaeve c. Ann Oncol. 2012 Dec;23(12):3091-3097. doi: 10.1093/annonc/mds204. Epub 2012 Aug 2. Ann Oncol. 2012. PMID: 22865782 Free article.
Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis.
van de Water W, Bastiaannet E, Hille ET, Meershoek-Klein Kranenbarg EM, Putter H, Seynaeve CM, Paridaens R, de Craen AJ, Westendorp RG, Liefers GJ, van de Velde CJ. van de Water W, et al. Oncologist. 2012;17(1):55-63. doi: 10.1634/theoncologist.2011-0037. Epub 2011 Dec 30. Oncologist. 2012. PMID: 22210087 Free PMC article. Clinical Trial.
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL Study Group. Blok EJ, et al. Breast Cancer Res Treat. 2018 Apr;168(2):413-420. doi: 10.1007/s10549-017-4601-1. Epub 2017 Dec 12. Breast Cancer Res Treat. 2018. PMID: 29230665 Free PMC article. Clinical Trial.
Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL and TEAM Study Groups. Blok EJ, et al. Eur J Cancer. 2018 May;95:59-67. doi: 10.1016/j.ejca.2018.03.014. Epub 2018 Apr 7. Eur J Cancer. 2018. PMID: 29635145 Clinical Trial.
Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
van Nes JG, Seynaeve C, Maartense E, Roumen RM, de Jong RS, Beex LV, Meershoek-Klein Kranenbarg WM, Putter H, Nortier JW, van de Velde CJ; Cooperating investigators of the Dutch TEAM trial. van Nes JG, et al. Among authors: seynaeve c. Ann Oncol. 2010 May;21(5):974-82. doi: 10.1093/annonc/mdp419. Epub 2009 Oct 29. Ann Oncol. 2010. PMID: 19875752 Free article. Clinical Trial.
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.
van Nes JG, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJ; Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trialists; Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Hozumi Y, Kerin MJ, Kieback DG, Meershoek-Klein Kranenbarg WM, Hille ET, Nortier JW. van Nes JG, et al. Among authors: seynaeve c. Br J Surg. 2010 May;97(5):671-9. doi: 10.1002/bjs.6962. Br J Surg. 2010. PMID: 20393978
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study.
van Nes JG, Fontein DB, Hille ET, Voskuil DW, van Leeuwen FE, de Haes JC, Putter H, Seynaeve C, Nortier JW, van de Velde CJ. van Nes JG, et al. Among authors: seynaeve c. Breast Cancer Res Treat. 2012 Jul;134(1):267-76. doi: 10.1007/s10549-012-2028-2. Epub 2012 Mar 28. Breast Cancer Res Treat. 2012. PMID: 22453754 Free PMC article. Clinical Trial.
Relevant impact of central pathology review on nodal classification in individual breast cancer patients.
Vestjens JHMJ, Pepels MJ, de Boer M, Borm GF, van Deurzen CHM, van Diest PJ, van Dijck JAAM, Adang EMM, Nortier JWR, Rutgers EJT, Seynaeve C, Menke-Pluymers MBE, Bult P, Tjan-Heijnen VCG. Vestjens JHMJ, et al. Among authors: seynaeve c. Ann Oncol. 2012 Oct;23(10):2561-2566. doi: 10.1093/annonc/mds072. Epub 2012 Apr 11. Ann Oncol. 2012. PMID: 22495317 Free article.
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO, van Schaik RH, Vletter-Bogaartz JM, van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, van de Velde CJ, Nortier JW, Gelderblom H, Guchelaar HJ. Dezentjé VO, et al. Among authors: seynaeve c. Breast Cancer Res Treat. 2013 Jul;140(2):363-73. doi: 10.1007/s10549-013-2619-6. Epub 2013 Jul 11. Breast Cancer Res Treat. 2013. PMID: 23842856 Clinical Trial.
340 results